Lipid Regulation of Autoimmunity
自身免疫的脂质调节
基本信息
- 批准号:7669287
- 负责人:
- 金额:$ 5.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acute-Phase ReactionAdhesivesAnimal ModelAnimalsAntigensApoptosisAtherosclerosisAttenuatedAutoimmune DiseasesAutoimmune ProcessAutoimmune ResponsesAutoimmunityB-LymphocytesBiological AssayBloodBlood CirculationBlood VesselsCD4 Positive T LymphocytesCellsChaperonin 60CholesterolChromatinChronicClinicalConditionDataDevelopmentDiseaseElevationEndothelial CellsEnsureEsterificationExperimental Animal ModelG-Protein-Coupled ReceptorsGenerationsGlomerulonephritisHistonesHomingHydrolysisHypercholesterolemia resultImmuneImmune responseImmunityIndividualInflammationInflammatoryInflammatory ResponseKnock-outLigandsLipidsLipoproteinsLow Density Lipoprotein ReceptorLupusLymphocyteLymphocyte ActivationLymphocyte DepletionLysophosphatidylcholinesMaintenanceMeasuresMediatingMedical SurveillanceMusNumbersPatientsPeripheralPhospholipasePhospholipidsPlayPopulationPredispositionProductionRegulationRheumatoid ArthritisRoleSymptomsSystemic Lupus ErythematosusT-LymphocyteTestingbasecell mediated immune responsecell motilityhypercholesterolemiainsightlymph nodesmonocytemutantnoveloxidationoxidized low density lipoproteinresearch studyresponsesynergismtrafficking
项目摘要
The increased susceptibility of patients with chronic inflammatory autoimmune diseases such as systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA) to the development of atherosclerosis is a major clinical
problem. This association is underlied by a synergistic inter-relationship between autoimmune and atherosclerotic
diseases which is also observed in experimental animal models of hypercholesterolemia. However, factors
common to chronic inflammation and hypercholesterolemia that contribute to this synergism remain poorly
characterized. Hypercholesterolemia is associated with the generation of pro-inflammatory phospholipids in the
circulation with etiological connections to chronic inflammatory autoimmune disease. One such phospholipid,
ysophosphatidylcholine (LPC), is a major pro-atherogenic product of lipoprotein oxidation and phospholipid
hydrolysis by pro-inflammatory phospholipases whose over-production is believed to play a pathophysiological
role in SLE. LPC stimulates T cell migration via G2A, a G protein-coupled receptor expressed predominantly in
ymphocytes and monocyte-derived cells. We recently determined that deletion of G2A in hypercholesterolemic
low-density lipoprotein receptor knockout (LDLR-/-) mice suppresses atherosclerosis. Hypercholesterolemia in
G2A-deficient (G2A-/-) LDLR-/- mice resulted in significant depletion of lymphocytes from peripheral lymph nodes
with concomitant reductions in the numbers of activated and effector CD4+ cells. This suggests that loss of
normal G2A-mediated migratory responses of circulating lymphocytes to elevations in blood LPC levels are
responsible for the development of lymphopenic lymph nodes. We hypothesize that G2A regulates adaptive
immune responses during an inflammatory response by promoting lymphocyte trafficking through lymph nodes in
response to transient elevations in circulating LPC levels to ensure efficient antigen surveillance. We propose that
the deregulation of this mechanism due to sustained elevations in LPC associated with hypercholesterolemia and
chronic inflammation contributes to the synergism between atherosclerotic and autoimmune diseases by
promoting T cell-mediated immune responses to auto-antigens. We will test this hypothesis by measuring the
impact of G2A deficiency on T cell entry into, and egress from, lymph nodes under normocholesterolemic and
hypercholesterolemic conditions. We will also evaluate atherosclerosis and autoimmunity in hypercholesterolemic
lupus-prone gld mice in the presence or absence of G2A function; we will determine whether loss of G2A function
in hypercholesterolemic gld mice suppresses autoimmune responses to classical lupus antigens, attenuates the
development of overt symptoms of autoimmunity, and results in reduced CD4+ T cell-mediated immune
responses to atherosclerosis-related auto-antigens. These studies will provide important insight into novel lipidmediated
mechanisms underlying the synergistic inter-relationship between autoimmunity and atherosclerosis
慢性炎症性自身免疫性疾病如系统性狼疮患者的易感性增加
红斑狼疮(SLE)和类风湿性关节炎(RA)发展为动脉粥样硬化是临床上的一个主要
问题.这种关联的基础是自身免疫和动脉粥样硬化之间的协同相互关系
在高胆固醇血症的实验动物模型中也观察到的疾病。然而,因素
常见于慢性炎症和高胆固醇血症,有助于这种协同作用仍然很差
表征了高胆固醇血症与肝细胞中促炎性磷脂的产生有关。
与慢性炎症性自身免疫性疾病的病因学联系。一种这样的磷脂,
溶血磷脂酰胆碱(LPC)是脂蛋白氧化和磷脂酰胆碱的主要促动脉粥样硬化产物,
促炎性磷脂酶的水解,其过度产生被认为在病理生理学上起作用,
在SLE中的作用LPC通过G2 A刺激T细胞迁移,G2 A是一种G蛋白偶联受体,主要在细胞中表达
淋巴细胞和单核细胞衍生的细胞。我们最近确定G2 A的缺失在高胆固醇血症患者中,
低密度脂蛋白受体敲除(LDLR-/-)小鼠抑制动脉粥样硬化。高胆固醇血症
G2 A缺陷(G2 A-/-)LDLR-/-小鼠导致外周淋巴结淋巴细胞显著耗竭
伴随着活化和效应CD 4+细胞数量的减少。这表明,
正常的G2 A介导的循环淋巴细胞对血液LPC水平升高的迁移反应,
负责淋巴细胞减少性淋巴结的发展。我们假设G2 A调节适应性
通过促进淋巴细胞通过淋巴结的运输,
以确保有效的抗原监测。我们建议
由于与高胆固醇血症相关的LPC持续升高,
慢性炎症有助于动脉粥样硬化和自身免疫性疾病之间的协同作用,
促进T细胞介导的对自身抗原的免疫应答。我们将通过测量
G2 A缺乏对正常胆固醇血症和高脂血症下T细胞进出淋巴结影响
高胆固醇血症我们还将评估高胆固醇血症患者的动脉粥样硬化和自身免疫性。
在存在或不存在G2 A功能的狼疮倾向gld小鼠中,我们将确定G2 A功能的丧失是否
在高胆固醇血症的gld小鼠中,抑制对经典狼疮抗原的自身免疫应答,减弱
发展自身免疫的明显症状,并导致CD 4 + T细胞介导的免疫功能降低。
对动脉粥样硬化相关自身抗原的反应。这些研究将为新型脂质介导的
自身免疫和动脉粥样硬化之间协同相互关系的潜在机制
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JANUSZ H KABAROWSKI其他文献
JANUSZ H KABAROWSKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JANUSZ H KABAROWSKI', 18)}}的其他基金
The role of the G2A receptor in Atherosclerosis
G2A受体在动脉粥样硬化中的作用
- 批准号:
7640997 - 财政年份:2007
- 资助金额:
$ 5.37万 - 项目类别:
The role of the G2A receptor in Atherosclerosis
G2A受体在动脉粥样硬化中的作用
- 批准号:
7500734 - 财政年份:2007
- 资助金额:
$ 5.37万 - 项目类别:
The role of the G2A receptor in Atherosclerosis
G2A受体在动脉粥样硬化中的作用
- 批准号:
7879341 - 财政年份:2007
- 资助金额:
$ 5.37万 - 项目类别:
The role of the G2A receptor in Atherosclerosis
G2A受体在动脉粥样硬化中的作用
- 批准号:
8111689 - 财政年份:2007
- 资助金额:
$ 5.37万 - 项目类别:
The role of the G2A receptor in Atherosclerosis
G2A受体在动脉粥样硬化中的作用
- 批准号:
7250560 - 财政年份:2007
- 资助金额:
$ 5.37万 - 项目类别:
相似海外基金
I-Corps: Translation Potential of Peptidic Ensembles as Novel Bio-adhesives
I-Corps:肽整体作为新型生物粘合剂的转化潜力
- 批准号:
2409620 - 财政年份:2024
- 资助金额:
$ 5.37万 - 项目类别:
Standard Grant
Architectural design of active adhesives
活性粘合剂的结构设计
- 批准号:
2403716 - 财政年份:2024
- 资助金额:
$ 5.37万 - 项目类别:
Standard Grant
Design of non-swellable adhesives for brain surgery using cyclodextrin inclusion polymer
使用环糊精包合物聚合物脑外科不可溶胀粘合剂的设计
- 批准号:
23H01718 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Meta-material adhesives for improved performance and functionalisation of bondlines
超材料粘合剂可提高粘合层的性能和功能化
- 批准号:
EP/W019450/1 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Fellowship
Light-propelled dental adhesives with enhanced bonding capability
具有增强粘合能力的光驱动牙科粘合剂
- 批准号:
10741660 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
DMREF: Accelerating the Design of Adhesives with Nanoscale Control of Thermomechanical Properties
DMREF:通过热机械性能的纳米级控制加速粘合剂的设计
- 批准号:
2323317 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Continuing Grant
Mag-Cure: A novel method for magnetically induced bonding and de-bonding of thermoset adhesives in the Automotive Industry
Mag-Cure:汽车行业中热固性粘合剂磁感应粘合和脱粘的新方法
- 批准号:
10062336 - 财政年份:2023
- 资助金额:
$ 5.37万 - 项目类别:
Collaborative R&D
Biodegradable, Biocompatible Pressure Sensitive Adhesives
可生物降解、生物相容性压敏粘合剂
- 批准号:
10677869 - 财政年份:2022
- 资助金额:
$ 5.37万 - 项目类别:
Poly(glycerol carbonate) pressure sensitive adhesives for the in vivo closure of alveolar pleural fistulae
用于体内闭合肺泡胸膜瘘的聚(甘油碳酸酯)压敏粘合剂
- 批准号:
10746743 - 财政年份:2022
- 资助金额:
$ 5.37万 - 项目类别:
Enhanced bio-production of difficult to make peptide ingredients for specialty adhesives and personal care
增强用于特种粘合剂和个人护理品的难以制造的肽成分的生物生产
- 批准号:
10021363 - 财政年份:2022
- 资助金额:
$ 5.37万 - 项目类别:
Investment Accelerator